Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia

Br J Haematol. 2019 Mar;184(6):1018-1021. doi: 10.1111/bjh.15204. Epub 2018 Jun 8.
No abstract available

Keywords: acute myeloid leukaemia (AML); new drug development; new drugs for leukaemia; oncology; pharmacokinetics.

Publication types

  • Clinical Trial, Phase I
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cytarabine / therapeutic use*
  • Female
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Male
  • Maximum Tolerated Dose
  • Middle Aged
  • Pteridines / administration & dosage
  • Pteridines / therapeutic use*
  • Salvage Therapy / methods

Substances

  • BI 6727
  • Pteridines
  • Cytarabine